8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Curcumin regulates the homeostasis of Th17/Treg and improves the composition of gut microbiota in type 2 diabetic mice with colitis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Diabetes mellitus ( DM) is one of the most common complications in patients with ulcerative colitis ( UC). Curcumin has a wide range of bioactive and pharmacological properties and is commonly used as an adjunct to the treatment of UC and DM. However, the role of curcumin in UC complicated by DM has not been elucidated. Therefore, this study was conducted to construct a model of UC complicating diabetes by inducing UC in DB mice (spontaneously diabetic) with dextran sodium sulfate. In this study, curcumin (100 mg/kg/day) significantly improved the symptoms of diabetes complicated by UC, with a lower insulin level, heavier weight, longer and lighter colons, fewer mucosal ulcers and less inflammatory cell infiltration. Moreover, compared to untreated DB mice with colitis, curcumin‐treated mice showed weaker Th17 responses and stronger Treg responses. In addition, curcumin regulated the diversity and relative abundance of intestinal microbiota in mice with UC complicated by DM at the phylum, class, order, family and genus levels. Collectively, curcumin effectively alleviated colitis in mice with type 2 diabetes mellitus by restoring the homeostasis of Th17/Treg and improving the composition of the intestinal microbiota

          Related collections

          Most cited references80

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A simple practice guide for dose conversion between animals and human

          Understanding the concept of extrapolation of dose between species is important for pharmaceutical researchers when initiating new animal or human experiments. Interspecies allometric scaling for dose conversion from animal to human studies is one of the most controversial areas in clinical pharmacology. Allometric approach considers the differences in body surface area, which is associated with animal weight while extrapolating the doses of therapeutic agents among the species. This review provides basic information about translation of doses between species and estimation of starting dose for clinical trials using allometric scaling. The method of calculation of injection volume for parenteral formulation based on human equivalent dose is also briefed.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Chemically induced mouse models of acute and chronic intestinal inflammation

            This protocol update describes how to generate mouse models of inflammatory bowel diseases and methods for analyzing disease progression.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The microbiome and inflammatory bowel disease

              Inflammatory bowel disease (IBD) is a chronic immune-mediated disease affecting the gastrointestinal tract. IBD consists of 2 subtypes: ulcerative colitis and Crohn disease. IBD is thought to develop as a result of interactions between environmental, microbial, and immune-mediated factors in a genetically susceptible host. Of late, the potential role of the microbiome in the development, progression, and treatment of IBD has been a subject of considerable interest and enquiry. Indeed, studies in human subjects have shown that the gut microbiome is different in patients with IBD compared with that in healthy control subjects. Other evidence in support of a fundamental role for the microbiome in patients with IBD includes identification of mutations in genes involved in microbiome-immune interactions among patients with IBD and epidemiologic observations implicating such microbiota-modulating risk factors as antibiotic use, cigarette smoking, levels of sanitation, and diet in the pathogenesis of IBD. Consequently, there has been much interest in the possible benefits of microbiome-modulating interventions, such as probiotics, prebiotics, antibiotics, fecal microbiota transplantation, and gene manipulation in the treatment of IBD. In this review we will discuss the role of the gut microbiome in patients with IBD; our focus will be on human studies.
                Bookmark

                Author and article information

                Contributors
                haimei79@163.com
                liuduanyong@163.com
                Journal
                Phytother Res
                Phytother Res
                10.1002/(ISSN)1099-1573
                PTR
                Phytotherapy Research
                John Wiley & Sons, Ltd. (Chichester, UK )
                0951-418X
                1099-1573
                02 March 2022
                April 2022
                : 36
                : 4 ( doiID: 10.1002/ptr.v36.4 )
                : 1708-1723
                Affiliations
                [ 1 ] Laboratory Animal Research Center for Science and Technology Jiangxi University of Traditional Chinese Medicine Nanchang China
                [ 2 ] Research and Development Department Jiangzhong Pharmaceutical Co., Ltd Nanchang China
                [ 3 ] Key Laboratory of Animal Model of TCM Syndromes of Depression Jiangxi University of Traditional Chinese Medicine Nanchang China
                [ 4 ] College of Traditional Chinese Medicine Jiangxi University of Traditional Chinese Medicine Nanchang China
                [ 5 ] Department of Postgraduate Jiangxi University of Traditional Chinese Medicine Nanchang China
                [ 6 ] Formula‐Pattern Research Center Jiangxi University of Traditional Chinese Medicine Nanchang China
                Author notes
                [*] [* ] Correspondence

                Hai‐Mei Zhao, Jiangxi University of Traditional Chinese Medicine, 1688 Meiling Road, Nanchang 330004, Jiangxi Province, China.

                Email: haimei79@ 123456163.com

                Duan‐Yong Liu, Jiangxi University of Traditional Chinese Medicine, 1688 Meiling Road, Nanchang 330004, Jiangxi Province, China.

                Email: liuduanyong@ 123456163.com

                Author information
                https://orcid.org/0000-0003-2761-8639
                https://orcid.org/0000-0001-8767-5251
                https://orcid.org/0000-0003-2855-2811
                Article
                PTR7404
                10.1002/ptr.7404
                9310646
                35234309
                37ffeb0b-5433-49de-8a3f-6fe7dde7f8a9
                © 2022 The Authors. Phytotherapy Research published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 18 January 2022
                : 17 November 2021
                : 22 January 2022
                Page count
                Figures: 7, Tables: 0, Pages: 16, Words: 11400
                Funding
                Funded by: 1050 Young Talents Project
                Award ID: 1141900603
                Funded by: Education Department of Jiangxi Province , doi 10.13039/501100009102;
                Award ID: GJJ196047
                Award ID: GJJ196049
                Award ID: GJJ201261
                Funded by: National Natural Science Foundation of China , doi 10.13039/501100001809;
                Award ID: 81760808
                Award ID: 82060799
                Funded by: Natural Science Foundation of Jiangxi Province , doi 10.13039/501100004479;
                Award ID: 20192ACB20015
                Award ID: 20202ACBL206026
                Funded by: Science and Technology Plan Project of Jiangxi Provincial Health and Health Commission
                Award ID: 202110121
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                April 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:25.07.2022

                Pharmacology & Pharmaceutical medicine
                colitis,curcumin,intestinal microbiota,th17/treg,type 2 diabetes mellitus

                Comments

                Comment on this article